Literature DB >> 8428296

Medullary thyroid carcinoma.

J M Dunn1, J R Farndon.   

Abstract

Medullary thyroid carcinoma accounts for 5-10 per cent of thyroid malignancies and occurs sporadically, and in three familial settings with autosomal dominant inheritance. Calcitonin, a 32 amino acid 3.5-kDa protein, is a biochemical marker of the tumour. Serum levels correlate with disease burden. Treatment initiated by screening allows disease removal at a premalignant phase: C cell hyperplasia. Genetic linkage studies locate the multiple endocrine neoplasia type 2A gene near the centromere of chromosome 10. Flanking genetic markers may allow polymorphic probes to examine DNA from a once-only blood sample to identify affected individuals. At what age thyroidectomy should be carried out in these patients is unclear.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8428296     DOI: 10.1002/bjs.1800800105

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  3 in total

1.  Medullary thyroid carcinoma in Northern Ireland, 1967-1997.

Authors:  S J Dolan; C F Russell
Journal:  Ann R Coll Surg Engl       Date:  2000-05       Impact factor: 1.891

2.  A case of spurious hypercalcitoninemia: a cautionary tale on the use of plasma calcitonin assays in the screening of patients with thyroid nodules for neoplasia.

Authors:  G I Uwaifo; A T Remaley; M Stene; J C Reynolds; P M Yen; R H Snider; K L Becker; N J Sarlis
Journal:  J Endocrinol Invest       Date:  2001-05       Impact factor: 4.256

3.  Medullary thyroid cancer: clinico-pathological profile and outcome in a tertiary care center in North India.

Authors:  Prateek Kumar Mehrotra; Anjali Mishra; Saroj Kanta Mishra; Gaurav Agarwal; Amit Agarwal; Ashok Kumar Verma
Journal:  World J Surg       Date:  2011-06       Impact factor: 3.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.